01 3Aiphagan
02 8Alphagan/Combigan
03 1Lumify
Main Therapeutic Indication : Ophthalmology
Currency : USD
2020 Revenue in Millions : 326
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 529
2020 Revenue in Millions : 326
Growth (%) : 62
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 346
2021 Revenue in Millions : 529
Growth (%) : -35
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 272
2022 Revenue in Millions : 346
Growth (%) : -21
Brimonidine Tartrate/Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2017 Revenue in Millions : 552
2016 Revenue in Millions : 546
Growth (%) : 1
Brimonidine Tartrate/Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2018 Revenue in Millions : 551
2017 Revenue in Millions : 552
Growth (%) : -0.10%
Brimonidine Tartrate/Timolol Maleate
Main Therapeutic Indication : Ophthalmology
Currency : USD
2016 Revenue in Millions : 546
2015 Revenue in Millions : 411
Growth (%) : 33
Main Therapeutic Indication : Ophthalmology
Currency : USD
2019 Revenue in Millions : 522
2018 Revenue in Millions : 551
Growth (%) : -5
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 108
2020 Revenue in Millions : 74
Growth (%) : 46
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 101
2020 Revenue in Millions : 0
Growth (%) : 100
LOOKING FOR A SUPPLIER?